What a Mammalian Expression System Does
A mammalian expression system is a platform that uses mammalian cells to produce recombinant proteins. Because these cells can perform human-like post-translational modifications, they are often the system of choice for therapeutic antibodies, complex multisubunit enzymes, and glycoproteins. The choice of host line, vector, and culture conditions directly affects yield, quality, and cost.
More from this site
Keep reading the latest coverage
Researchers select a mammalian expression system when bacterial or insect systems fail to produce a functional, correctly folded protein. The trade-off is higher production cost and longer timelines, but the payoff is a molecule that behaves predictably in human biological assays and clinical settings.
Common Host Cell Lines
The most widely used mammalian hosts are Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK293) cells, and mouse myeloma (NS0 or SP2/0) lines. Each line has distinct strengths:
- CHO cells dominate industrial biomanufacturing because they are adapted to serum-free suspension culture and have a well-characterized, stable genome.
- HEK293 cells transfect efficiently and are favored for rapid, small-scale production of research-grade proteins and viral vectors.
- NS0 and SP2/0 cells are often used for monoclonal antibody discovery and screening workflows.
Expression Vector Design
A mammalian expression vector typically includes a strong promoter (such as CMV or EF1α), a polyadenylation signal, a selectable marker, and a multicloning site. For stable production, the construct integrates into the host genome, often through random integration or targeted insertion. For transient high-yield runs, episomal plasmids suffice.
Codons are optimized for the host species, and signal peptides direct the protein into the secretory pathway. Vector backbone choice affects copy number, epigenetic silencing risk, and the ease of scale-up in bioreactors.
The Transfection and Selection Workflow
The standard workflow begins with transient transfection to screen for high-producing clones, followed by stable line generation. Cells are exposed to DNA and a transfection reagent such as polyethyleneimine or lipofectamine, or they are electroporated for harder-to-transfect lines.
After selection with an antibiotic or metabolic marker, surviving colonies are isolated, expanded, and screened by ELISA or Western blot. Top clones are subcloned to ensure monoclonality, then profiled for growth rate, productivity, and glycosylation consistency before the cell bank is created.
Post-Translational Modifications and Product Quality
The primary advantage of a mammalian expression system is its capacity for authentic post-translational modifications. Glycosylation patterns, disulfide bond formation, and proteolytic processing closely mirror those in human cells, which is critical for biologics that must be immunologically tolerated.
Glycan profiles can vary by cell line and culture conditions, so manufacturers often engineer the host to humanize glycosylation pathways or use media supplements to guide the outcome. Analytical methods such as mass spectrometry and lectin blotting are used to verify the modification profile.
Scale-Up and Manufacturing
Mammalian production scales from shake flasks to stirred-tank bioreactors using fed-batch or perfusion strategies. CHO cells are grown in chemically defined, animal-component-free media to meet regulatory requirements for therapeutic products.
Critical process parameters include temperature shift, osmolality, dissolved oxygen, and pH control. Bioreactor scale-up must maintain viable cell density and productivity while minimizing aggregate formation and protease activity, which can degrade the product.
Trade-Offs and Alternatives
Despite their advantages, mammalian systems are slower and more expensive than microbial alternatives. A stable CHO clone can take six to twelve months to develop, and production costs per gram are high.
For simpler proteins, researchers may choose an E. coli expression system for speed and low cost, or a baculovirus-insect cell system for proteins requiring some eukaryotic processing. The decision hinges on the molecule's complexity, the required modification profile, and the intended application.